CL2023001744A1 - Agonistas duales del receptor de amilina y calcitonina y usos de los mismos - Google Patents
Agonistas duales del receptor de amilina y calcitonina y usos de los mismosInfo
- Publication number
- CL2023001744A1 CL2023001744A1 CL2023001744A CL2023001744A CL2023001744A1 CL 2023001744 A1 CL2023001744 A1 CL 2023001744A1 CL 2023001744 A CL2023001744 A CL 2023001744A CL 2023001744 A CL2023001744 A CL 2023001744A CL 2023001744 A1 CL2023001744 A1 CL 2023001744A1
- Authority
- CL
- Chile
- Prior art keywords
- amylin
- compounds
- calcitonin receptor
- dual agonists
- dyslipidemia
- Prior art date
Links
- 108010001789 Calcitonin Receptors Proteins 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title abstract 2
- 108091005466 amylin receptors Proteins 0.000 title abstract 2
- 102100038520 Calcitonin receptor Human genes 0.000 title 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 title 1
- 230000009977 dual effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 2
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 102000055006 Calcitonin Human genes 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 abstract 1
- 229960004015 calcitonin Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/585—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente descripción se refiere al campo de la medicina. Más particularmente, la descripción se encuentra en el campo del tratamiento de la diabetes, la obesidad y/o la dislipidemia. La descripción se refiere a compuestos que son agonistas tanto de los receptores de calcitonina como de amilina y pueden reducir la ingesta de alimentos, el peso corporal, la glucosa y/o los triglicéridos, por lo que pueden usarse para tratar la diabetes, la obesidad y/o la dislipidemia. La presente descripción también incluye composiciones farmacéuticas que contienen tales compuestos y usos terapéuticos de tales compuestos y composiciones.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063127186P | 2020-12-18 | 2020-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001744A1 true CL2023001744A1 (es) | 2024-01-19 |
Family
ID=80113494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001744A CL2023001744A1 (es) | 2020-12-18 | 2023-06-14 | Agonistas duales del receptor de amilina y calcitonina y usos de los mismos |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11541123B2 (es) |
| EP (1) | EP4262977A1 (es) |
| JP (1) | JP7569487B2 (es) |
| KR (1) | KR20230146004A (es) |
| CN (1) | CN117729941A (es) |
| AR (1) | AR124295A1 (es) |
| AU (1) | AU2021401314B2 (es) |
| CA (1) | CA3201167A1 (es) |
| CL (1) | CL2023001744A1 (es) |
| CO (1) | CO2023007807A2 (es) |
| CR (1) | CR20230252A (es) |
| DO (1) | DOP2023000121A (es) |
| EC (1) | ECSP23045245A (es) |
| IL (1) | IL303743A (es) |
| MX (1) | MX2023007240A (es) |
| PE (1) | PE20231560A1 (es) |
| TW (3) | TW202317173A (es) |
| WO (1) | WO2022133187A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022210988B9 (en) | 2021-01-20 | 2023-12-14 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
| WO2024050289A1 (en) | 2022-08-29 | 2024-03-07 | Eli Lilly And Company | Compositions for oral delivery |
| WO2024163535A1 (en) * | 2023-01-31 | 2024-08-08 | Eli Lilly And Company | Gip/glp1/gcg tri-receptor agonists and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4639510A (en) * | 1985-10-04 | 1987-01-27 | Armour Pharmaceutical Company | (1-S-acetamidomethyl cysteine, 7-alanine)calcitonin |
| DK2389388T3 (en) | 2009-01-22 | 2017-05-01 | Keybioscience Ag | TREATMENT FOR Obesity |
| LT3321278T (lt) | 2013-11-14 | 2019-03-12 | Keybioscience Ag | Kalcitonino mimetikai, skirti ligų ir sutrikimų gydymui |
| CN106687474A (zh) | 2014-09-04 | 2017-05-17 | 诺和诺德股份有限公司 | 新型胰淀素和降钙素受体激动剂 |
| GB201707955D0 (en) | 2017-05-18 | 2017-07-05 | Keybioscience Ag | Dual amylin and calcitonin receptor agonists for treating diseases and disorders |
| SG11202100128UA (en) * | 2018-07-23 | 2021-02-25 | Lilly Co Eli | Gip/glp1 co-agonist compounds |
| GB201813678D0 (en) * | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Acylated calcitonin mimetics |
| TWI764209B (zh) * | 2019-08-01 | 2022-05-11 | 美商美國禮來大藥廠 | Gipr促效劑化合物 |
-
2021
- 2021-12-09 TW TW112100099A patent/TW202317173A/zh unknown
- 2021-12-09 TW TW110146048A patent/TWI790850B/zh active
- 2021-12-09 AR ARP210103420A patent/AR124295A1/es unknown
- 2021-12-09 TW TW112100098A patent/TW202317174A/zh unknown
- 2021-12-17 AU AU2021401314A patent/AU2021401314B2/en active Active
- 2021-12-17 CN CN202180084836.2A patent/CN117729941A/zh active Pending
- 2021-12-17 MX MX2023007240A patent/MX2023007240A/es unknown
- 2021-12-17 CR CR20230252A patent/CR20230252A/es unknown
- 2021-12-17 US US17/554,022 patent/US11541123B2/en active Active
- 2021-12-17 CA CA3201167A patent/CA3201167A1/en active Pending
- 2021-12-17 IL IL303743A patent/IL303743A/en unknown
- 2021-12-17 EP EP21847828.7A patent/EP4262977A1/en active Pending
- 2021-12-17 PE PE2023001882A patent/PE20231560A1/es unknown
- 2021-12-17 KR KR1020237024537A patent/KR20230146004A/ko unknown
- 2021-12-17 WO PCT/US2021/063990 patent/WO2022133187A1/en active Application Filing
- 2021-12-17 JP JP2023538041A patent/JP7569487B2/ja active Active
-
2022
- 2022-10-28 US US18/050,659 patent/US20230190945A1/en active Pending
- 2022-10-28 US US18/050,604 patent/US20230190944A1/en active Pending
-
2023
- 2023-06-14 CL CL2023001744A patent/CL2023001744A1/es unknown
- 2023-06-14 DO DO2023000121A patent/DOP2023000121A/es unknown
- 2023-06-15 CO CONC2023/0007807A patent/CO2023007807A2/es unknown
- 2023-06-16 EC ECSENADI202345245A patent/ECSP23045245A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024500163A (ja) | 2024-01-04 |
| CA3201167A1 (en) | 2022-06-23 |
| IL303743A (en) | 2023-08-01 |
| KR20230146004A (ko) | 2023-10-18 |
| TW202237172A (zh) | 2022-10-01 |
| TWI790850B (zh) | 2023-01-21 |
| CN117729941A (zh) | 2024-03-19 |
| EP4262977A1 (en) | 2023-10-25 |
| US20220193245A1 (en) | 2022-06-23 |
| AU2021401314A9 (en) | 2024-07-04 |
| MX2023007240A (es) | 2023-09-04 |
| AU2021401314B2 (en) | 2024-07-04 |
| DOP2023000121A (es) | 2023-09-15 |
| CR20230252A (es) | 2023-11-15 |
| PE20231560A1 (es) | 2023-10-03 |
| US20230190944A1 (en) | 2023-06-22 |
| WO2022133187A1 (en) | 2022-06-23 |
| AR124295A1 (es) | 2023-03-15 |
| TW202317174A (zh) | 2023-05-01 |
| US20230190945A1 (en) | 2023-06-22 |
| AU2021401314A1 (en) | 2023-06-29 |
| ECSP23045245A (es) | 2023-07-31 |
| US11541123B2 (en) | 2023-01-03 |
| JP7569487B2 (ja) | 2024-10-18 |
| CO2023007807A2 (es) | 2023-08-28 |
| TW202317173A (zh) | 2023-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023007807A2 (es) | Agonistas duales del receptor de amilina y calcitonina y usos de los mismos | |
| BR112022022331A2 (pt) | Método para melhorar efeitos terapêuticos positivos de um psicodélico, composição, e método para tratar um paciente | |
| BR112015010203A8 (pt) | composição para a prevenção ou tratamento de diabetes, complicações diabéticas ou diabesidade, uso de um conjugado análogo da oxintomodulina, e, método para a preparação de um conjugado análogo da oxintomodulina | |
| DOP2019000068A (es) | Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip | |
| CL2019001143A1 (es) | Dímeros de insulina, agonistas parciales del receptor de insulina (divisional solicitud 201701288) | |
| BR112019011139A8 (pt) | conjugados que compreendem um agonista dual de glp/glucagon, um ligante e ácido hilaurônico | |
| CL2023003893A1 (es) | Semaglutida para el tratamiento de esteatohepatitis no alcohólica. | |
| ECSP23066120A (es) | Agonistas del receptor de amilina de acción prolongada y usos de estos | |
| CO2023008866A2 (es) | Coagonistas de los receptores de glp-1 y amilina | |
| Onimus et al. | The surprising efficiency of Artemisia annua powder capsules | |
| BR112023010891A2 (pt) | Compostos polipeptídicos modificados com lactama | |
| CO2023013976A2 (es) | Composición farmacéutica y uso del agonista dual del receptor de gip y glp-1 | |
| León-Ariza et al. | A systematic review of “myokines and metabolic regulation” | |
| CO2022007501A2 (es) | Métodos y composiciones para el tratamiento del síndrome de rett | |
| BR112017022478A2 (pt) | composição farmacêutica de liberação sustentada que contém rivastigmina | |
| UY38473A (es) | Formulaciones farmacéuticas para una administración subcutánea | |
| Arrastía et al. | Delirio de parasitosis | |
| Balmaceda et al. | PCN21 ESTUDIO DE COSTO EFECTIVIDAD DE NIVOLUMAB PARA EL TRATAMIENTO DE SEGUNDA LINEA DEL CARCINOMA DE CELULAS RENALES METASTASICO DESDE LA PERSPECTIVA DEL SISTEMA DE SALUD PUBLICO CHILENO | |
| CL2023001183A1 (es) | Proteínas de fusión para el tratamiento de enfermedades | |
| Fonseca | The therapeutic role of Liraglutide in the modulation of adipose tissue angiogenesis | |
| GB190103513A (en) | An Improved Remedy in Salve or Composition for Healing External Complaints of Human Body & Animal Diseases | |
| Varlamova et al. | Efficacy of combined niclosamide-based drug against Anoplocephala spp. of different types and ages. | |
| Weerakoon et al. | Chronic anti-inflammatory activity of Sudarshana powder on adjuvant-induced arthritis in rats | |
| Polanco-Hernández et al. | Research Article Synergistic Effect of Lupenone and Caryophyllene Oxide against Trypanosoma cruzi | |
| Konovalova et al. | THE EFFECT OF THE VITAMINE D PREPARATIONS ON THE OUTCOMES OF MYOCARDIAL INFACTION IN PATIENTS WITH TYPE 2 DIABETES, OSTEOPOROSIS OR OSTEOPENIA |